Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $636.2 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 2.73% year-over-year to $636.2 million in Q1 2026; TTM through Mar 2026 was $636.2 million, a 2.73% increase from a year earlier, with the FY2025 full-year figure at $553.0 million, down 11.9% from the prior year.
• Current Deferred Revenue advanced to $636.2 million in Q1 2026 per REGN's latest filing, from $553.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $636.2 million in Q1 2026 and bottomed at $381.1 million in Q2 2023.
• The 5-year median for Current Deferred Revenue is $545.6 million (2025), against an average of $527.1 million.
• Across the five-year window, Current Deferred Revenue plunged 32.7% in 2023 and jumped 53.77% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $477.9 million in 2022, then fell by 3.98% to $458.9 million in 2023, then surged by 36.78% to $627.7 million in 2024, then fell by 11.9% to $553.0 million in 2025, then climbed by 15.05% to $636.2 million in 2026.
• Per Business Quant, the three latest REGN Current Deferred Revenue figures stand at $636.2 million (Q1 2026), $553.0 million (Q4 2025), and $545.6 million (Q3 2025).